FDA approves Roche's Tecentriq in combination with Avastin and chemotherapy for NSCLC
Roche announced the FDA approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial treatment of people with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumour aberrations. December 07, 2018